



Speakers



Dr Wolfram Eisenreich
Boehringer Ingelheim Pharma GmbH
& Co. KG, Germany



Dr Jörg Engelbergs
Paul- Ehrlich-Institut, Germany



Sonja Estermann
F. Hoffmann-La Roche Ltd,
Switzerland



Dr Hiltrud Horn
Horn Pharmaceutical Consulting,
Germany



Dr Claus-Dieter Schiller
F. Hoffmann-La Roche AG,
Switzerland

How to Write the Quality Part of an IMPD



Live Online Training on 06/07 October 2021



Highlights

- Drug substance and drug product quality data – what has to be considered
- Substantial amendments and notification obligations
- Stability considerations
- Quality information of comparator products and placebos
- IMPD for biotech products
- Manufacture of clinical trial formulations
- Planning of an IMPD
- Quality information required for global clinical trials
- Specific aspects for a paediatric Q-IMPD

Requirements to chemical and pharmaceutical quality documentation for an IMP dossier

Objectives

This Live Online Training highlights the key principles of the **Quality Part of an IMPD** for Investigational Medicinal Products, both of chemical and biotechnological origin. You will get to know the essential aspects relevant for compiling the IMPD Quality Part and you will learn

- How to prepare and process the quality related information for drug substance and drug product
- How to manage and document changes concerning quality data
- How to consider quality parameters of drug substance and drug product with potential clinical relevance
- How to describe the manufacturing process development for a biotech IMP
- How to process and document stability data for an IMPD of a biotech product

Background

An IMPD is required for every Investigational Medicinal Product (IMP) to be used in a clinical study, regardless of whether it is the test product itself, a reference product already authorised or a placebo. The IMPD includes summaries of information related to the quality, manufacture and control of the IMP as well as data from non-clinical and clinical studies. Furthermore, it contains an overall risk-benefit assessment and critical analyses of the non-clinical and clinical data related to the potential risks and benefits of the proposed study.

In March 2006 the CHMP “Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation concerning Investigational Medicinal Products in Clinical Trials” was published in Chapter III of Volume 10 of EudraLex.

Another CHMP Guidance for Biologicals entitled “Guideline on the Requirements for Quality Documentation concerning Biological Investigational Medicinal Products in Clinical Trials” was adopted in March 2012 and became effective in April 2012.

Target Audience

This Live Online Training is designed for all persons involved in the compilation of IMPDs who want to become familiar with the requirements for the quality documentation of investigational medicinal products. The training will be of interest in particular for personnel from Regulatory Affairs as well as for personnel from Quality Assurance, Quality Control and Production.

Programme

Why do we Need an IMPD? Legal Framework and Regulatory Requirements

- Regulatory requirements
- Challenges
- Practical hints
- Sources of information

General Requirements to an IMPD

- Structure and content
- Planning
- Preparation
- Submission

Quality Documentation for a Biotech IMPD – Manufacturing Process and Analytical Characterisation

- Description of the manufacturing process, control of critical steps
- Manufacturing process development
- Characterisation and control of the active substance

Quality Documentation for a Biotech IMPD – Product Control and Stability Studies

- Control of excipients
- Specifications, batch analysis
- Stability data
- Substantial amendments

Drug Substance – Description of the Manufacturing Process

- Control of critical steps and intermediates
- Control of Impurities
- Analytical procedures and validation requirements
- Justification of specifications and stability data

Writing of the Drug Product Section of an IMPD

- Key aspects
- Practical examples

Quality Information of Authorised Modified and Non-modified Comparator Products

- Description and composition
- Summary of Product Characteristics (SmPC)
- Additional information for Phase II and Phase III clinical trials
- Quality information on existing active substances in bio-equivalence studies
- Quality information on placebo products



Case Study: Planning of an IMPD

This Case Study will focus on the essentials of clinical trials. The participants will get practical advice on how to successfully plan and prepare IMPDs.

How to Manage and Document Changes to IMP Quality Data – Substantial Amendments

- Changes that need to be notified
- Amendments that are to be regarded as “substantial”
- When have changes to be notified?
- Some examples

How to Handle Paediatric Formulations

- What is a Paediatric Investigation Plan (PIP)?
Legal framework and content of the quality part
- Specific aspects for the formulation development (taste, preservatives, etc.)
- Specific aspects for a paediatric Q-IMPD

Quality Information Required for Global Clinical Trials

- Role of investigators brochure
- IMPD vs IND?
- Other countries e.g. Canada, Japan, China etc. – one dossier for all?

Speakers



Dr Wolfram Eisenreich, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

Dr Eisenreich is a pharmacist by training and received his PhD at the Ludwig-Maximilians-University Munich in 2002. He worked for one year as a Postdoctoral Scientist at GlaxoSmithKline at three different departments and locations in the USA. In 2003, he joined Boehringer Ingelheim and headed formulation development groups in Biberach, Germany and Ridgefield, USA. Since 2010 he is heading the Central Clinical Trial Bulk Manufacture Solids group at Boehringer Ingelheim. Amongst other things, he is now responsible for blinding of comparator products, development of matching placebo products and authoring of the respective IMP documents.



Dr Jörg Engelbergs, Paul-Ehrlich-Institut (PEI), Germany Federal Agency for Vaccines and Biomedicines

Dr Engelbergs studied biology at the university of Düsseldorf and Duisburg-Essen. After his PhD he worked in different positions at the German Cancer Center before he joined the PEI in 2006 as Scientific-Regulatory Expert Biomedicines (Quality, Non-Clinic, Pers. Medicines - Biomarker/CDx).



Sonja Estermann, F. Hoffmann-La Roche Ltd, Switzerland

Ms Estermann has more than 20 years experience in regulatory, working since 2004 at F. Hoffmann-La Roche Ltd as Global Technical Regulatory Manager with expertise in paediatrics. Prior to Roche she worked in Regulatory Affairs at Pfizer Switzerland. She started her career as a community pharmacist and head of QC/FTL "Qualified Person" in the Pharmacy Hotz/Galepharm Switzerland. Ms Estermann holds an M.S. in Pharmacy from the University of Basel, Switzerland and a post diploma HF in Business Economics.



Dr Hiltrud Horn, Horn Pharmaceutical Consulting, Germany

Dr Horn is managing director of HORN PHARMACEUTICAL CONSULTING with focus on CMC, GMP and Regulatory Affairs. She started in pharma industry in 1990 and held several managerial positions within Hoffmann-La Roche in Basel and Knoll (Abbott) with global responsibility within QC / QA / Regulatory Affairs / Project Management / Medical Writing.



Dr Claus-Dieter Schiller, F. Hoffmann-La Roche AG, Switzerland

Dr Schiller has studied Chemistry at the University in Regensburg. He received his PhD at the Institute of Pharmaceutical Chemistry in Regensburg. Since 1995 he is working in Global Technical Registration of F. Hoffmann La Roche. Dr Schiller has held different positions within Technical Registration dealing with different aspects of filings of synthetic products ranging from clinical trials, NDAs to post-approval changes. In his present position he is group manager of Documentation & Training.

If the bill-to-address deviates from the specifications on the right, please fill out here:

Reservation Form (Please complete in full)



How to Write the Quality Part of an IMPD Live Online Training on 06/07 October 2021

Title, first name, surname

Department

Company

Important: Please indicate your company's VAT ID Number

Purchase Order Number, if applicable

City

ZIP Code

Country

Phone / Fax

E-Mail (Please fill in)

CONCEPT HEIDELBERG

P.O. Box 101764

Fax +49 (0) 62 21/84 44 34

D-69007 Heidelberg

GERMANY

General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees:
 - Cancellation until 2 weeks prior to the conference 10%.
 - Cancellation until 1 week prior to the conference 50%.
 - Cancellation within 1 week prior to the conference 100%.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors,

or speakers without notice or to cancel an event.

If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

Terms of payment: Payable without deductions within 10 days after receipt of invoice.

Important: This is a binding registration and above fees are due in case of can-

cellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message.

In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed!) (As of January 2012).

German law shall apply. Court of jurisdiction is Heidelberg.

Privacy Policy: By registering for this event, I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at <https://www.gmp-compliance.org/privacy-policy>). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.



Date of the Live Online Training

Wednesday, 06 October 2021, 09.00 – 17.30 h CEST

Thursday, 07 October 2021, 09.00 – 16.00 h CEST

Technical Requirements

For our Live Online Training Courses and Webinars, we use Cisco WebEx, one of the leading suppliers of online meetings.

At <http://www.webex.com/test-meeting.html> you can check if your system meets the necessary requirements for the participation at a WebEx meeting and at the same time install the necessary plug-in. Please just enter your name and email address for the test. If the installation is not possible because of your rights for the computer system, please contact your IT department. WebEx is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate, plus VAT)

ECA Members € 1,590

APIC Members € 1,690

Non-ECA Members € 1,790

EU GMP Inspectorates € 895

The conference fee is payable in advance after receipt of invoice.

Registration

Via the attached reservation form, by e-mail or by fax message.

Or you register online at www.gmp-compliance.org.

Presentations/Certificate

The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language

The official conference language will be English.

Your Benefit

Internationally Acknowledged Certificate from ECA Academy

The EU GMP Guide requires: „... All personnel should be aware of the principles of Good Manufacturing Practice that affect them and receive initial and continuing training,...“. This is why you receive an acknowledged participant certificate, which lists the contents of the seminar in detail and with which you document your training.

Organisation and Contact

ECA has entrusted Concept Heidelberg with the organisation of this event.

CONCEPT HEIDELBERG

P.O. Box 10 17 64

D-69007 Heidelberg

Telefon +49(0) 62 21/84 44-0

Telefax +49(0) 62 21/84 44 34

E-Mail: info@concept-heidelberg.de

www.concept-heidelberg.com

For questions regarding content please contact:

Ms Anne Günster (Operations Director) at
+49(0)62 21/84 44 50, or per e-mail at
gunster@concept-heidelberg.de.

For questions regarding organisation please contact:

Ms Nicole Bach (Organisation Manager) at
+49(0)62 21/84 44 22, or per e-mail at
bach@concept-heidelberg.de.